

04/07/08 In Vivo Blog

Hank Plain is Bullish on Drug-eluting Stents

Two stent companies recorded capital this week, clearly showing venture interest remains strong in the devices.

First, [CardioMind Inc. drew down \\$22 million](#), the second tranche of a \$33 million financing it raised last year. The capital came after the company hit the milestone of instituting its first-in-man trials, aka Care II. Then, Tryton Medical Inc., [secured a \\$14 million Series C](#) to help pay for development of its bifurcated stent.

“We’re still bullish in the drug-eluting stent market,” says Hank Plain, general partner of Morgenthaler Ventures, who helped start stent-maker Xtent Inc., a company [we wrote about recently in \*IN VIVO\* the magazine](#).

Look for more on where VCs are playing their stent bets in the April issue of *START-UP*.